{ "company": "Guardant Health", "ticker": "GH", "period": { "from": "2026-03-07", "to": "2026-04-06", "days": 30 }, "sentiment_breakdown": { "positive": 71, "negative": 63, "neutral": 66 }, "synthesis": { "executive_summary": "Sentiment analysis for Guardant Health (GH) from 2026-03-07 to 2026-04-06. Analyzed 200 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Show HN: Open Source 'Conductor + Ghostty'", "date": "2026-03-27", "source": "news", "score": 0.883 }, { "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026", "date": "2026-04-01", "source": "alpha_vantage", "score": 0.881 }, { "title": "Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke", "date": "2026-03-26", "source": "news", "score": 0.88 }, { "title": "Heath Goldfields Has Brought Renewed Hope To Prestea-Bogoso -Group", "date": "2026-03-31", "source": "news", "score": 0.844 }, { "title": "Determination of factors that allow cryogenic nanoscopy with high power illumination without devitrification", "date": "2026-03-31", "source": "news", "score": 0.832 }, { "title": "Donors cheer up SHS Arts students for decorating Asokwa Interchange", "date": "2026-03-30", "source": "news", "score": 0.827 }, { "title": "5 popular OpenClaw integrations that will level up your productivity", "date": "2026-04-02", "source": "news", "score": 0.822 }, { "title": "Effects of a native avian predator (weka; Gallirallus australis) and colony density on breeding success of a burrow-nesting seabird (tītī; Ardenna grisea)", "date": "2026-04-02", "source": "news", "score": 0.802 }, { "title": "Aura Reports Updated Mineral Reserves and Mineral Resources For The Year-Ended 2025, Highlighting year of Significant Growth in Mineral Reserve and Resource Portfolio", "date": "2026-04-01", "source": "news", "score": 0.778 }, { "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "date": "2026-03-27", "source": "alpha_vantage", "score": 0.772 } ], "top_negative": [ { "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "date": "2026 Apr 1", "source": "pubmed", "score": -1.0 }, { "title": "Police Gun Down Suspected Armed Robber on Atebubu–Ejura Highway", "date": "2026-03-30", "source": "news", "score": -0.95 }, { "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "date": "2026-03-27", "source": "news", "score": -0.945 }, { "title": "Nsein chief gives Lower Axim counter three-month ultimatum to vacate his land", "date": "2026-04-01", "source": "news", "score": -0.905 }, { "title": "Businessman Jailed 24 Months for GH¢180,000 Visa Fraud", "date": "2026-03-27", "source": "news", "score": -0.9 }, { "title": "Two Jailed for Stealing Motorbike Worth GH¢10,500", "date": "2026-03-27", "source": "news", "score": -0.883 }, { "title": "Biobanking of gynecologic cancer biospecimens: Development, quality control, and translational applications", "date": "2026-03-31", "source": "news", "score": -0.869 }, { "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial", "date": "2026-03-27", "source": "news", "score": -0.869 }, { "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "date": "2026 Mar 2", "source": "pubmed", "score": -0.869 }, { "title": "Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A", "date": "2026-03-26", "source": "news", "score": -0.791 } ], "raw_data": { "total_items": 200, "items": [ { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation After Japan ENHERTU Approval Backed By InfinityAI Real World Evidence", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-after-japan-enhertu-approval-ba", "date": "2026-04-04", "summary": "Guardant Health (GH) is in focus after Japan approved ENHERTU for certain HER2 positive cancers, partly supported by Guardant's InfinityAI platform. Despite a 131.22% one-year return, the stock has seen a recent decline, prompting questions about its valuation. While a narrative suggests a 28.2% undervaluation with a fair value of $130.64 due to AI integration and expanded clinical applications, a sales multiple analysis indicates the stock might appear rich compared to the broader healthcare se", "sentiment_score": 0.326566, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CPO gains stock from RSU vesting and tax withholding", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-56ee3da8ffc2.html", "date": "2026-04-03", "summary": "Guardant Health's Chief People Officer, Terilyn J. Monroe, received 8,019 shares of common stock on April 1, 2026, due to the vesting of restricted stock units. Subsequently, 4,187 shares were withheld by the company at $91.15 per share to cover tax obligations. After these transactions, Monroe directly holds 24,822 shares of Guardant Health common stock, reflecting routine equity compensation rather than open-market trading.", "sentiment_score": 0.009859, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) CMO nets shares as RSUs vest and taxes withheld", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-962fc1dbb93d.html", "date": "2026-04-02", "summary": "Guardant Health's Chief Medical Officer, Craig Eagle, acquired 11,400 shares of common stock through the vesting of Restricted Stock Units (RSUs) on April 1, 2026. As part of this process, 5,779 shares were withheld by the company to cover tax obligations. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.", "sentiment_score": 0.036058, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) co-CEO reports RSU vesting, tax-share withholdings and over 2.1M shares held", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-87afe3f0262c.html", "date": "2026-04-02", "summary": "Guardant Health's co-CEO, Helmy Eltoukhy, reported routine equity compensation activity involving Restricted Stock Units (RSUs) that vested on March 31 and April 1, 2026. These transactions resulted in the conversion of tens of thousands of RSUs into common stock, with shares withheld by the company to cover tax obligations. Following these events, Eltoukhy, through a revocable trust, holds over 2.1 million shares of common stock, in addition to directly holding 68,011 restricted stock units.", "sentiment_score": 0.037245, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "11,213 Guardant Health (GH) RSUs vest; 4,750 shares withheld for tax", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-7025cfabc0b9.html", "date": "2026-04-02", "summary": "Guardant Health's Chief Commercial Officer, Chris Freeman, had 11,213 Restricted Stock Units (RSUs) vest on April 1, 2026. To cover tax obligations, 4,750 shares were withheld by the company at a price of $91.15 per share. Following these transactions, Freeman directly held 60,034 shares of Guardant Health common stock.", "sentiment_score": 0.027352, "sentiment_label": "Neutral", "relevance_score": 0.960187, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "SWS Partners Has $7.89 Million Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-sws-partners-has-789-million-holdings-in-guardant-health-inc-gh-2026-04-02/", "date": "2026-04-02", "summary": "SWS Partners reduced its stake in Guardant Health (NASDAQ:GH) by 18.3% in the fourth quarter, holding 77,209 shares valued at $7.89 million, representing 1.5% of its portfolio. Guardant Health reported Q4 EPS of -$0.50, missing estimates, but revenue increased by 39.4% to $281.3 million. Analysts have a \"Moderate Buy\" consensus rating with an average target price of $125.95, despite recent insider selling totaling $2.51 million.", "sentiment_score": 0.088797, "sentiment_label": "Neutral", "relevance_score": 0.989169, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Allspring Global Investments Holdings LLC Reduces Stock Holdings in Guardant Health, Inc. $GH", "url": "https://www.marketbeat.com/instant-alerts/filing-allspring-global-investments-holdings-llc-reduces-stock-holdings-in-guardant-health-inc-gh-2026-04-02/", "date": "2026-04-02", "summary": "Allspring Global Investments Holdings LLC significantly reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 1.9% in the fourth quarter, selling 12,256 shares and now owning 618,599 shares valued at $62.94 million. Insider transactions also show sales of 23,250 shares totaling $2.51 million in the last 90 days. Despite these reductions, analysts maintain a \"Moderate Buy\" rating with an average price target of $125.95 for Guardant Health, a precision oncology company.", "sentiment_score": 0.139048, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health Stock Rises on Japan Regulatory News for Daiichi Sankyo Drug - News and Statistics", "url": "https://www.indexbox.io/blog/guardant-health-stock-gains-on-japan-drug-approval-using-infinityai-data/", "date": "2026-04-02", "summary": "Guardant Health's stock saw a significant increase following the approval of a cancer drug by Daiichi Sankyo in Japan, which utilized real-world evidence from Guardant's InfinityAI platform. This event highlights the growing role of AI and real-world data in regulatory decisions for new treatments, despite the historical volatility of Guardant Health's stock. The article also includes extensive information about an antisera industry report for Japan, unrelated to the main news.", "sentiment_score": 0.343962, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NasdaqGS:GH) Stock Forecast & Analyst Predictions", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/future", "date": "2026-04-02", "summary": "Guardant Health (NasdaqGS:GH) is forecasted to experience significant growth, with earnings projected to increase by 55.1% and revenue by 20.9% annually. Despite being unprofitable for the next three years, its revenue growth is expected to outpace the US market. Analysts have also recently increased its price target, signaling positive sentiment for the company's future performance.", "sentiment_score": 0.409013, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director at Guardant Health (GH) acquires 155 shares via RSUs", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-0a86624789a6.html", "date": "2026-04-01", "summary": "Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock by exercising Restricted Stock Units. This transaction on March 31, 2026, was a routine equity-compensation event at an exercise price of $0.00 per share. Following this, Krognes' direct holdings in Common Stock increased to 19,208 shares, and he retains 463 Restricted Stock Units.", "sentiment_score": 0.008759, "sentiment_label": "Neutral", "relevance_score": 0.303789, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health gets oncology innovation accolade at Healthcare Asia Medtech Awards 2026", "url": "https://mugglehead.com/guardant-health-gets-oncology-innovation-accolade-at-healthcare-asia-medtech-awards-2026/", "date": "2026-04-01", "summary": "Guardant Health Inc. (NASDAQ: GH) (FRA: 5GH) received the Oncology Product Innovation of the Year award at the Healthcare Asia Medtech Awards 2026 for its Shield multi-cancer detection test. The award comes shortly after Guardant launched Shield in Hong Kong, Singapore, and the Philippines, partnering with Manulife to offer the test to insurance customers. The Shield test, a methylation-based blood test, screens for 10 common cancers with high specificity, improving early detection and patient o", "sentiment_score": 0.408265, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.881, "confidence": 0.88 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) and Verana Health Announces New Partnership", "url": "https://www.insidermonkey.com/blog/guardant-health-gh-and-verana-health-announces-new-partnership-1727963/?amp=1", "date": "2026-03-31", "summary": "Guardant Health (NASDAQ:GH) and Verana Health have announced a new partnership to provide biopharmaceutical researchers with access to Guardant's clinicogenomic testing data and Verana's EHR datasets. This collaboration aims to accelerate the development of new therapies and improve patient care by allowing researchers to connect molecular biomarkers with treatment decisions and clinical outcomes. Guardant Health specializes in precision oncology, using data, blood-based tests, and advanced anal", "sentiment_score": 0.407784, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Why Is Guardant Health (GH) Stock Soaring Today", "url": "https://www.tradingview.com/news/stockstory:4270c6473094b:0-why-is-guardant-health-gh-stock-soaring-today/", "date": "2026-03-31", "summary": "Guardant Health (GH) stock saw a 5.9% increase after the company announced that its InfinityAI platform's real-world evidence contributed to the approval of the cancer drug ENHERTU® in Japan. This development validates Guardant's AI technology in precision oncology. Despite the recent jump, the stock remains volatile and is down 9.2% year-to-date and 21.2% below its 52-week high.", "sentiment_score": 0.007192, "sentiment_label": "Neutral", "relevance_score": 0.330672, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health real-world data supports Japan approval of ENHERTU for HER2-positive tumors", "url": "https://www.msn.com/en-us/health/other/guardant-health-real-world-data-supports-japan-approval-of-enhertu-for-her2-positive-tumors/ar-AA1ZJdPW?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-31", "summary": "Guardant Health's real-world data has supported the Japan Pharmaceuticals and Medical Devices Agency's approval of ENHERTU for treating HER2-positive tumors. This approval represents a significant step forward in personalized medicine for these cancer types, leveraging genomic profiling for treatment decisions. The data likely demonstrated the effectiveness or necessity of identifying HER2 status in patients.", "sentiment_score": 0.62952, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.681, "confidence": 0.68 } }, { "source": "alpha_vantage", "title": "The Bull Case For Guardant Health (GH) Could Change Following Japan’s ENHERTU Approval Using Its AI Data", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/the-bull-case-for-guardant-health-gh-could-change-following", "date": "2026-03-31", "summary": "Guardant Health's InfinityAI and Guardant360 platforms helped secure regulatory approval for Daiichi Sankyo’s ENHERTU in Japan, demonstrating the growing role of AI-driven real-world data in oncology drug approvals. While this reinforces the value of Guardant's data assets, the company still faces challenges with cash burn and achieving profitability. The approval, alongside partnerships like Verana Health, solidifies Guardant's position in AI-enabled oncology data but raises execution risks in ", "sentiment_score": 0.311346, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.477, "confidence": 0.48 } }, { "source": "alpha_vantage", "title": "Guardant Health Inc (GH) Trading Down 3.96% on Mar 30", "url": "https://www.gurufocus.com/news/8756885/guardant-health-inc-gh-trading-down-396-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "Guardant Health Inc (GH) experienced a 3.96% decline in its stock price on March 30, trading down to $84.61. While Wall Street analysts have an average target price of $129.67, suggesting a potential upside, GuruFocus estimates a different fair value of $67.08, implying a downside from the current price. The stock's trading volume was significantly higher than its average daily volume during this period.", "sentiment_score": -0.253173, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan", "url": "https://www.businesswire.com/news/home/20260330846159/en/Guardant-Healths-InfinityAI-Real-World-Evidence-Supports-Approval-of-ENHERTU-for-Previously-Treated-Patients-with-HER2-Positive-Metastatic-Solid-Tumors-in-Japan", "date": "2026-03-30", "summary": "Guardant Health's InfinityAI platform provided crucial real-world evidence, alongside clinical trial data, to support the recent approval of ENHERTU® in Japan. This approval, granted by Japan’s Ministry of Health, Labour and Welfare, is for treating HER2-positive metastatic solid cancers refractory to standard treatments. The collaboration with Daiichi Sankyo highlights the increasing importance of real-world data in expanding access to targeted therapies for rare biomarker-defined patient popul", "sentiment_score": 0.489667, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.735, "confidence": 0.74 } }, { "source": "alpha_vantage", "title": "Guardant Health to present new cancer research while stock trades lower amid strong sell signals", "url": "https://tradersunion.com/news/companies/show/1818093-guardant-health-drops-3-96percent-today/", "date": "2026-03-29", "summary": "Guardant Health is set to present 28 abstracts at the AACR26 event, showcasing advancements in cancer diagnostics and research, particularly in methylation-based tumor classification and multiomic testing. Despite this upcoming presentation of new cancer research, the company's stock has experienced a 3.96% intraday drop, trading lower amid strong sell signals and sustained bearish momentum. Technical indicators suggest further downside risk, with the stock positioned below key moving averages a", "sentiment_score": -0.646408, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "alpha_vantage", "title": "Guardant Health Shares Fall as Market Reacts to Conflict, Policy Deadlines | 2026 - News and Statistics", "url": "https://www.indexbox.io/blog/guardant-health-stock-drops-amid-market-uncertainty-and-low-consumer-confidence/", "date": "2026-03-28", "summary": "Guardant Health's stock declined in afternoon trading, reflecting broader market unease fueled by international conflict and upcoming policy deadlines. This market sentiment also pushed consumer confidence to a three-month low, and the company's shares are now trading below their year-to-date peak and are worth less than their value five years ago. The article also provides details on a report about the composite laboratory reagents industry in the United States, including market analysis, trade", "sentiment_score": -0.645288, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "alpha_vantage", "title": "Why Guardant Health (GH) Stock Is Falling Today", "url": "https://www.tradingview.com/news/stockstory:a4995f8d7094b:0-why-guardant-health-gh-stock-is-falling-today/", "date": "2026-03-27", "summary": "Guardant Health (GH) stock fell 3% today due to escalating uncertainty from the U.S.-Iran conflict and Trump administration policy deadlines, which also caused major indices to drop. This follows a 3.4% dip almost a month ago driven by higher-than-expected wholesale inflation data. Guardant Health's shares are highly volatile and have fallen 16.7% year-to-date, trading significantly below its 52-week high.", "sentiment_score": -0.420531, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "alpha_vantage", "title": "Guardant Health wins at Healthcare Asia Medtech Awards 2026", "url": "https://healthcareasiamagazine.com/co-written-partner/event-news/guardant-health-wins-healthcare-asia-medtech-awards-2026", "date": "2026-03-27", "summary": "Guardant Health Pte Ltd won the Oncology Product Innovation of the Year at the Healthcare Asia Medtech Awards 2026 for its ShieldTM Multi-cancer Detection (MCD) test. This blood test screens for 10 types of cancers, demonstrating 99% overall specificity and 74% sensitivity across six aggressive cancers in recent data. The Shield MCD test has also received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).", "sentiment_score": 0.407966, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.772, "confidence": 0.77 } }, { "source": "alpha_vantage", "title": "Tempus AI Reinforces Market Position With Collaborations in 2026", "url": "https://www.tradingview.com/news/zacks:5e5cf70e2094b:0-tempus-ai-reinforces-market-position-with-collaborations-in-2026/", "date": "2026-03-26", "summary": "Tempus AI (TEM) is strengthening its market position in 2026 through strategic collaborations with pharmaceutical companies, healthcare institutions, and technology innovators. These partnerships aim to improve clinical outcomes and accelerate drug development by leveraging Tempus's AI expertise and proprietary platforms. Notable collaborations include work with Daiichi Sankyo on an ADC program, Median Technologies for lung nodule characterization, Blood Cancer United for a pediatric AML registr", "sentiment_score": 0.029313, "sentiment_label": "Neutral", "relevance_score": 0.331321, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "http://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-03-25", "summary": "Guardant Health (GH) is partnering with Manulife to introduce its Shield multi-cancer detection test across Asia. This collaboration aims to provide enhanced cancer screening options in the region, leveraging Manulife's network to expand access to Guardant Health's diagnostic technology. The initiative represents a significant step in making advanced multi-cancer detection more widely available.", "sentiment_score": 0.422545, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health Ignites 5.6% Surge: A Volatile Breakout or a Trap for the Unwary?", "url": "https://www.bitget.com/news/detail/12560605304566", "date": "2026-03-25", "summary": "Guardant Health (GH) experienced a 5.63% intraday surge to $89.245, driven by a new partnership with Manulife, despite technical indicators like the RSI being deeply oversold. While the rally shows short-term bullish momentum and potential for breakout past the 30-day moving average, it faces resistance around the $90 psychological barrier and requires sustained movement above $95 to confirm a trend reversal. Options traders are targeting calls with high leverage and liquidity, signaling aggress", "sentiment_score": 0.311665, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Cancer drug researchers gain combined patient and genomics data", "url": "https://www.stocktitan.net/news/GH/verana-health-and-guardant-health-partner-to-advance-precision-2sbofpkxcb3q.html", "date": "2026-03-24", "summary": "Verana Health and Guardant Health have partnered to combine Verana's EHR datasets with Guardant's clinicogenomic testing data, aiming to accelerate oncology drug development and enhance real-world treatment insights. This collaboration expands access to over 95 million patients and more than 30 academic medical centers, providing biopharmaceutical researchers with comprehensive data to understand patient journeys and validate molecular biomarkers. The partnership is expected to streamline drug d", "sentiment_score": 0.328861, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.956981, "sentiment": { "label": "negative", "score": -0.25, "confidence": 0.25 } }, { "source": "alpha_vantage", "title": "Verana and Guardant’s RWE Stack Aims to Solve Precision Oncology’s Data Challenges—Driving Growth Through Recurring Revenue and Broader Data Collections", "url": "https://www.bitget.com/amp/news/detail/12560605299239", "date": "2026-03-24", "summary": "Verana Health and Guardant Health are collaborating to build a robust real-world evidence (RWE) data platform to address precision oncology's data challenges. This partnership integrates Guardant's clinicogenomic datasets with COTA's AI-enhanced oncology data, acquired through Verana's merger, to provide comprehensive insights for drug development. The strategy focuses on high-margin, recurring revenue streams from companion diagnostics and expanding into new therapeutic areas like bladder and p", "sentiment_score": 0.040185, "sentiment_label": "Neutral", "relevance_score": 0.317157, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data", "url": "https://www.prnewswire.com/news-releases/verana-health-and-guardant-health-partner-to-advance-precision-medicine-with-real-world-data-302719285.html", "date": "2026-03-24", "summary": "Verana Health and Guardant Health have partnered to combine their real-world data resources to accelerate precision medicine, particularly in oncology and urology. This collaboration will allow biopharmaceutical researchers to access curated EHR data alongside clinicogenomic testing data, enhancing the understanding of patient journeys and aiding therapy development. The combined data sets will help validate correlations between molecular biomarkers, treatment decisions, and clinical outcomes, a", "sentiment_score": 0.408636, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director’s RSU vesting adds 264 common shares", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5b119b371c3f.html", "date": "2026-03-24", "summary": "Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units (RSUs) into common shares. This transaction, part of a routine equity compensation event, increased his direct holdings to 4,487 common shares and 8,184 RSUs. The vested RSUs are from an award granted on November 8, 2024, with a vesting schedule of 25% on the one-year anniversary and the remainder monthly over three years.", "sentiment_score": 0.040925, "sentiment_label": "Neutral", "relevance_score": 0.327981, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) Valuation Check As New Manulife Partnership Expands Shield Testing In Asia", "url": "https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-valuation-check-as-new-manulife-partnersh", "date": "2026-03-23", "summary": "Guardant Health (GH) is under scrutiny after announcing a partnership with Manulife to expand its Shield multi-cancer detection blood test in Asia, starting April 2026. Despite recent share price volatility, the company has shown strong long-term momentum with an 84.77% one-year return, yet some models suggest it's significantly undervalued. The article debates whether the market has already factored in future growth, highlighting potential valuation risks from a high P/S ratio compared to the i", "sentiment_score": 0.275029, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.303, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/health/other/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-22", "summary": "Guardant Health (GH) has partnered with Manulife to introduce its Shield multi-cancer detection test in Asia. This collaboration aims to provide early cancer detection solutions to a broader population in the region through Manulife's network. The Shield test is designed to detect multiple types of cancer at early stages, potentially improving patient outcomes.", "sentiment_score": 0.432567, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Why Guardant Health’s (GH) 2026 screening story reinforced Piper Sandler’s bullish view", "url": "https://www.msn.com/en-us/money/companies/why-guardant-health-s-gh-2026-screening-story-reinforced-piper-sandler-s-bullish-view/ar-AA1YTUKn?ocid=finance-verthp-feeds", "date": "2026-03-21", "summary": "This article discusses Piper Sandler's maintained bullish outlook on Guardant Health (GH), specifically reinforced by insights from the company's 2026 screening strategy. The analyst firm highlighted a conference presentation that detailed key upcoming milestones and reiterated confidence in Guardant Health's future growth prospects.", "sentiment_score": 0.81242, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) partners with Manulife to launch Shield multi-cancer detection test in Asia", "url": "https://www.msn.com/en-us/money/general/guardant-health-gh-partners-with-manulife-to-launch-shield-multi-cancer-detection-test-in-asia/ar-AA1Z4xZA", "date": "2026-03-21", "summary": "Guardant Health (GH) has partnered with Manulife to launch its Shield multi-cancer detection test in Asia. This collaboration aims to make the early cancer detection test accessible to a broader population in the region, leveraging Manulife's network. The Shield test is designed to detect multiple types of cancer from a single blood draw.", "sentiment_score": 0.408571, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Insider Sell: Musa Tariq Sells Shares of Guardant Health Inc (GH)", "url": "https://www.gurufocus.com/news/8728137/insider-sell-musa-tariq-sells-shares-of-guardant-health-inc-gh", "date": "2026-03-20", "summary": "Musa Tariq, a Director at Guardant Health Inc (GH), sold 348 shares of the company on March 18, 2026, bringing his total ownership to 8,394 shares. Over the past year, Tariq has sold a total of 4,489 shares with no purchases. Guardant Health Inc is considered significantly overvalued with a price-to-GF-Value ratio of 1.68, based on its trading price of $88.09 against a GF Value of $52.52.", "sentiment_score": -0.308607, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Insider Selling: Guardant Health (NASDAQ:GH) Director Sells 348 Shares of Stock", "url": "https://www.marketbeat.com/instant-alerts/insider-selling-guardant-health-nasdaqgh-director-sells-348-shares-of-stock-2026-03-19/", "date": "2026-03-19", "summary": "Guardant Health (NASDAQ:GH) Director Musa Tariq sold 348 shares of the company's stock on March 18, 2026, for a total value of $30,655.32. This sale reduced his stake by 3.98% to 8,394 shares. The company's stock traded up 2.1% to $89.08, and despite missing Q4 EPS estimates, revenue increased by 39.4% year-over-year.", "sentiment_score": -0.181266, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) director sells 348 company shares", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-426fc16d4cb8.html", "date": "2026-03-19", "summary": "Guardant Health director Tariq Musa sold 348 shares of the company's common stock on March 18, 2026, at an average price of $88.09 per share. This open-market transaction was reported via a Form 4 SEC filing. Following the sale, Musa directly holds 8,394 shares of Guardant Health stock.", "sentiment_score": -0.253121, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director Tariq Musa sells $30,655 in stock", "url": "https://m.investing.com/news/insider-trading-news/guardant-health-gh-director-tariq-musa-sells-30655-in-stock-93CH-4571897?ampMode=1", "date": "2026-03-19", "summary": "Guardant Health (GH) director Tariq Musa sold 348 shares of common stock for $30,655 on March 18, 2026, bringing his total direct ownership to 8,394 shares. This insider sale occurs as the company's stock trades near $89.08. Separately, Guardant Health recently reported its Q4 2025 results, with several analysts reaffirming or increasing price targets due to strong performance and a positive outlook for commercial expansion and cost management.", "sentiment_score": 0.120464, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics", "url": "https://www.investing.com/news/company-news/cathie-woods-ark-sells-guardant-health-stock-buys-arcturus-therapeutics-93CH-4569651", "date": "2026-03-19", "summary": "Cathie Wood's ARK sold 11,757 shares of Guardant Health (NASDAQ:GH) totaling over $1 million through its ARKG ETF, continuing a trend of reducing its position in the company. Concurrently, ARK purchased 33,864 shares of Arcturus Therapeutics Holdings (NASDAQ:ARCT) for $216,390, indicating a strategic shift towards innovative therapeutics. A smaller sale of Standard Biotools (NASDAQ:LAB) shares also occurred, reflecting ARK's ongoing portfolio reallocation within the biotech sector.", "sentiment_score": -0.385594, "sentiment_label": "Bearish", "relevance_score": 0.974018, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Director at Guardant Health (GH) receives 232 shares via RSUs", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-5d6041acaa59.html", "date": "2026-03-18", "summary": "Guardant Health director Manuel Hidalgo Medina received 232 common shares through the exercise of restricted stock units (RSUs) on March 17, 2026, as part of his equity compensation. These shares were converted at a price of $0.00 per share, increasing his direct holdings to 1,425 shares. The RSU award originated from a grant on July 17, 2024, with a four-year vesting schedule.", "sentiment_score": 0.02769, "sentiment_label": "Neutral", "relevance_score": 0.306643, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares", "url": "https://www.stocktitan.net/sec-filings/GH/144-guardant-health-inc-sec-filing-295c113b5a16.html", "date": "2026-03-18", "summary": "Guardant Health (NASDAQ: GH) has filed a Form 144 indicating proposed insider sales of shares. The filing details planned dispositions of Common Stock linked to restricted stock lapses, with events scheduled for January 15, 2026 (250 shares) and February 15, 2026 (98 shares), handled by Charles Schwab & Co., Inc. This notice acts as a procedural disclosure of intent to sell rather than a record of completed transactions.", "sentiment_score": 0.0317, "sentiment_label": "Neutral", "relevance_score": 0.962809, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership", "url": "https://www.businesswire.com/news/home/20260316025112/en/Guardant-Health-Launches-Shield-Multi-Cancer-Detection-MCD-Test-in-Multiple-Markets-in-Asia-with-Manulife-Partnership", "date": "2026-03-18", "summary": "Guardant Health, Inc. announced the launch of its Shield multi-cancer detection (MCD) test in several Asian markets through a partnership with Manulife. This collaboration will provide eligible Manulife customers in Hong Kong, Singapore, and the Philippines access to the blood-based test, which screens for 10 common cancers, starting in April 2026. The initiative aims to improve early cancer detection and screening participation in a region where cancer remains a leading cause of death.", "sentiment_score": 0.404006, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026", "url": "https://www.biospace.com/press-releases/guardant-health-to-present-28-abstracts-highlighting-advances-in-tumor-typing-therapy-selection-and-expanded-utility-of-multiomic-tissue-and-liquid-biopsy-testing-at-aacr-2026", "date": "2026-03-18", "summary": "Guardant Health and its collaborators will present 28 abstracts, including 3 oral sessions, at the AACR Annual Meeting in April 2026. The presentations will showcase advances in methylation-based tumor classification and liquid biopsy technology, highlighting the utility of Guardant360 Tissue and Guardant360 Liquid in tumor typing and therapy selection. Key data includes high accuracy of Guardant360 Tissue in determining tissue of origin and expanded clinical actionability of Guardant360 Liquid,", "sentiment_score": 0.493618, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Blood tests flag new primary cancers and actionable results in AACR data", "url": "https://www.stocktitan.net/news/GH/guardant-health-to-present-28-abstracts-highlighting-advances-in-bapvicsrazan.html", "date": "2026-03-18", "summary": "Guardant Health will present 28 abstracts at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, highlighting advances in its liquid biopsy technology. Key findings include the high accuracy of Guardant360 Tissue in determining cancer origin, the expanded utility of Guardant360 Liquid in identifying actionable findings for breast and colorectal cancer patients, and Guardant Reveal's potential to detect new primary malignancies during minimal residual disease monitor", "sentiment_score": 0.310502, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock", "url": "https://www.marketbeat.com/instant-alerts/guardant-health-nasdaqgh-cfo-sells-26112000-in-stock-2026-03-17/", "date": "2026-03-18", "summary": "Guardant Health (NASDAQ:GH) CFO Michael Brian Bell sold 3,000 shares of the company's stock for $261,120.00 on March 16, 2026, reducing his stake by 6.44%. The company recently missed EPS expectations in its latest earnings report but exceeded revenue estimates. Guardant Health stock traded at $88.75 mid-day, below its 50-day and 200-day simple moving averages, and institutional investors own approximately 92.6% of the outstanding shares.", "sentiment_score": 0.038726, "sentiment_label": "Neutral", "relevance_score": 0.323906, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-4dd8254703cb.html", "date": "2026-03-17", "summary": "Guardant Health's Chief Legal Officer, John G. Saia, acquired additional common stock through the vesting of performance-based and time-based Restricted Stock Units (RSUs) on March 15, 2026. After the transactions, and accounting for shares withheld for tax obligations, Mr. Saia directly owns 56,903 shares of Guardant Health common stock. The filing details how 4,622 shares were retained by the company at $85.49 per share to cover tax withholdings related to the RSU vesting.", "sentiment_score": 0.048363, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "alpha_vantage", "title": "Guardant Health (GH) director acquires 249 shares via RSU vesting", "url": "https://www.stocktitan.net/sec-filings/GH/form-4-guardant-health-inc-insider-trading-activity-78f740c8c862.html", "date": "2026-03-17", "summary": "Guardant Health director Tariq Musa converted 249 restricted stock units (RSUs) into common stock on March 15, 2026, as part of a scheduled vesting. This transaction increased his direct holdings to 8,742 common shares, with an additional 2,999 RSUs remaining. The RSUs, granted on March 6, 2023, vest over four years, with 25% vesting on the first anniversary and the rest monthly over the subsequent three years.", "sentiment_score": 0.043859, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Survey Supports Blood Tests for Colorectal Cancer Screening", "url": "https://www.curetoday.com/view/survey-supports-blood-tests-for-colorectal-cancer-screening", "date": "2026-03-17", "summary": "A new national survey indicates that 92% of adults eligible for colorectal cancer screening believe blood-based tests should be widely accessible and covered by insurance. These tests could significantly increase screening participation, with 77% of respondents stating they would be less likely to delay screening if a blood test were available. The survey highlights that blood tests could serve as a crucial entry point to screening, potentially overcoming common barriers associated with traditio", "sentiment_score": 0.432398, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "alpha_vantage", "title": "Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH)", "url": "https://www.insidermonkey.com/blog/heres-why-artisan-small-cap-fund-bets-on-guardant-health-gh-1718418/", "date": "2026-03-17", "summary": "Artisan Small Cap Fund highlighted its new position in Guardant Health, Inc. (NASDAQ: GH) in its Q4 2025 investor letter. Guardant Health specializes in liquid biopsy diagnostics for cancer detection and monitoring. Despite the fund's investment, Insider Monkey suggests that some AI stocks offer greater potential for higher and faster returns than Guardant Health.", "sentiment_score": 0.437898, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health launches Shield Multi-Cancer Detection Test in APAC market", "url": "https://www.biospectrumasia.com/news/54/27363/guardant-health-launches-shield-multi-cancer-detection-test-in-apac-market.html", "date": "2026-03-17", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) laboratory developed test (LDT) in key Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in average-risk individuals aged 45 or older. The initiative is supported by a partnership with Manulife, aiming to enhance early cancer detection access in the region.", "sentiment_score": 0.488767, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Guardant Health launches multi-cancer blood test in Asia through Manulife partnership", "url": "https://mugglehead.com/guardant-health-launches-multi-cancer-blood-test-in-asia-through-manulife-partnership/", "date": "2026-03-17", "summary": "Guardant Health (NASDAQ: GH) has launched its Shield multi-cancer detection blood test in several Asian markets through a partnership with Manulife Financial Corporation (TSE: MFC). The test, aimed at individuals aged 45 and older, screens for 10 common cancers using a blood sample. This expansion into Hong Kong, Singapore, and the Philippines, starting in April 2026, aims to improve early cancer detection rates in regions where cancer remains a leading cause of death.", "sentiment_score": 0.461364, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Singapore's Guardant Health launches Shield Multi-Cancer Detection (MCD) Test in APAC market", "url": "https://www.biospectrumasia.com/news/26/27363/singaporesguardant-health-launches-shield-multi-cancer-detection-mcd-test-in-apac-market.html", "date": "2026-03-17", "summary": "Guardant Health has launched its Shield multi-cancer detection (MCD) test in several Asian markets including Hong Kong, Singapore, and the Philippines, starting April 2026. This blood test screens for 10 common cancers in individuals aged 45 or older and aims to enhance early detection and screening participation in the APAC region. The initiative includes a partnership with Manulife, marking a significant step in making innovative early cancer detection technologies accessible.", "sentiment_score": 0.631664, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Wattsupwiththat.com", "title": "Demonstrating the Reverse Greenhouse Effect in the Laboratory – PART1", "description": "Laboratory experiments explore infrared emission of greenhouse gases under normal pressure, raising questions about atmospheric heat transfer and radiative assumptions.", "url": "https://wattsupwiththat.com/2026/04/05/demonstrating-the-reverse-greenhouse-effect-in-the-laboratory/", "date": "2026-04-05", "published_at": "2026-04-05T09:00:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "torchtext2 added to PyPI", "description": "Add your description here", "url": "https://pypi.org/project/torchtext2/", "date": "2026-04-04", "published_at": "2026-04-04T10:48:30Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: RemembrallMCP – code dependency graph for agents and memory", "description": "After watching Claude Code and Codex keep running Explore in my codebase over and over, I started to think that there must be a better way. RemembrallMCP is my attempt to fix this.RemembrallMCP gives agents two things most memory tools don't:1. Persistent Mem…", "url": "https://github.com/cdnsteve/remembrallmcp", "date": "2026-04-04", "published_at": "2026-04-04T06:39:29Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "parol-pygen 0.1.0", "description": "Python parser generator/runtime consuming parol export JSON", "url": "https://pypi.org/project/parol-pygen/", "date": "2026-04-03", "published_at": "2026-04-03T14:25:06Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Zumly – a library for building zooming user interfaces", "description": "Article URL: https://github.com/zumerlab/zumly\nComments URL: https://news.ycombinator.com/item?id=47625640\nPoints: 1\n# Comments: 1", "url": "https://github.com/zumerlab/zumly", "date": "2026-04-03", "published_at": "2026-04-03T11:53:42Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Three Remanded Over Alleged Land cruiser Theft in Tarkwa", "description": "The Circuit Court in Tarkwa, presided over by Her Honour Bernice Mensimah Akoh, has remanded three persons into custody for their alleged involvement in a vehicle theft syndicate operating in the area. The accused persons are Kojo Amponsah, also known as “Kam…", "url": "https://thechronicle.com.gh/three-remanded-over-alleged-land-cruiser-theft-in-tarkwa/", "date": "2026-04-03", "published_at": "2026-04-03T11:24:01Z", "sentiment": { "label": "positive", "score": 0.361, "confidence": 0.36 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Dispatch Rider Jailed 10 Years for Robbing Diplomat’s Secretary", "description": "The Circuit Court at Dansoman has sentenced a 24-year-old dispatch rider to 10 years’ imprisonment for robbing the Secretary to the Namibian High Commissioner in Ghana. The convict, Daniel Asiuebi, pleaded guilty simpliciter to two counts of robbery and causi…", "url": "https://thechronicle.com.gh/dispatch-rider-jailed-10-years-for-robbing-diplomats-secretary/", "date": "2026-04-03", "published_at": "2026-04-03T11:21:38Z", "sentiment": { "label": "negative", "score": -0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "Seclists.org", "title": "Re: [vim-security] Vim tabpanel modeline escape affects Vim", "description": "Posted by Salvatore Bonaccorso on Apr 03Hi,\n\nAccording to https://www.cve.org/CVERecord?id=CVE-2026-34714 the\nassigner is MITRE CNA itself.\n\nRegards,\nSalvatore", "url": "https://seclists.org/oss-sec/2026/q2/20", "date": "2026-04-03", "published_at": "2026-04-03T09:51:48Z", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "Bulinews.com", "title": "Former Germany coach Joachim Löw linked with World Cup job", "description": "Joachim Löw, who won the World Cup with Germany in 2014, is said to be close to a return to coaching.Citing “multiple sources,” Ghanasoccernet.com reports that Löw is close to being appointed Gh...", "url": "https://bulinews.com/former-germany-coach-joachim-low-linked-world-cup-job", "date": "2026-04-03", "published_at": "2026-04-03T09:08:00Z", "sentiment": { "label": "positive", "score": 0.572, "confidence": 0.57 } }, { "source": "news", "source_name": "Pypi.org", "title": "release-cli added to PyPI", "description": "AI-assisted CLI release manager powered by Backboard", "url": "https://pypi.org/project/release-cli/", "date": "2026-04-03", "published_at": "2026-04-03T00:11:17Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "memex-oss added to PyPI", "description": "Institutional knowledge extraction for engineering teams", "url": "https://pypi.org/project/memex-oss/", "date": "2026-04-02", "published_at": "2026-04-02T16:25:08Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "TechRadar", "title": "5 popular OpenClaw integrations that will level up your productivity", "description": "A practical look at five of the most popular OpenClaw integrations, covering messaging, productivity, developer tools, and smart home control.", "url": "https://www.techradar.com/pro/5-popular-openclaw-integrations-that-will-level-up-your-productivity", "date": "2026-04-02", "published_at": "2026-04-02T14:43:31Z", "sentiment": { "label": "positive", "score": 0.822, "confidence": 0.82 } }, { "source": "news", "source_name": "Plos.org", "title": "Football (Soccer) refereeing and cardiovascular health: A scoping review", "description": "Background Physical and psychological stress can precipitate Acute Coronary Syndrome (ACS) events. Football (soccer) is a popular sport globally, with referees covering significant distances, often at high-intensity during a match, and facing potentially inte…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346360", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Plos.org", "title": "Availability and affordability of essential medicines for non-communicable disease management in primary healthcare: Evidence from three municipalities in Ghana", "description": "Background Non-communicable diseases (NCDs) cause 74% of global deaths, disproportionately affecting LMICs like Ghana. Chronic treatment remains hindered by medicine shortages and high costs, consuming over 50% of the minimum wage incomes. Despite Ghana’s NCD…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346140", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.226, "confidence": 0.23 } }, { "source": "news", "source_name": "Plos.org", "title": "Effects of a native avian predator (weka; Gallirallus australis) and colony density on breeding success of a burrow-nesting seabird (tītī; Ardenna grisea)", "description": "As island ecosystems are restored, native predators are recovering and re-establishing interactions with their prey. However, compared with widely-publicised impacts of invasive predators, little is known about the dynamics and stability of native predator-pr…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0346357", "date": "2026-04-02", "published_at": "2026-04-02T14:00:00Z", "sentiment": { "label": "positive", "score": 0.802, "confidence": 0.8 } }, { "source": "news", "source_name": "YEN.COM.GH", "title": "Former Health Minister Dr Bernard Okoe-Boye Summoned Before PAC", "description": "The former Health Minister, Dr Bernard Okoe-Boye, has been summoned by PAC over GH¢20 million in mobilisation funds for the Parliamentary Hospital.", "url": "https://yen.com.gh/politics/302253-former-health-minister-dr-bernard-okoe-boye-summoned-pac/", "date": "2026-04-02", "published_at": "2026-04-02T12:36:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Clawd Pets – 90 animated SVG pets, pure CSS, no dependencies", "description": "Article URL: https://github.com/abderrahimghazali/clawd-pet\nComments URL: https://news.ycombinator.com/item?id=47613069\nPoints: 2\n# Comments: 0", "url": "https://github.com/abderrahimghazali/clawd-pet", "date": "2026-04-02", "published_at": "2026-04-02T11:39:38Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Seclists.org", "title": "Re: [vim-security] Vim tabpanel modeline escape affects Vim", "description": "Posted by Christian Brabandt on Apr 02Tianyu Chen schrieb am Donnerstag, den 02. April 2026:\n\nYes, but Github did not assign it. Someone else did and GH did barely \nnotify me of this already existing CVE.\n\nThanks,\nChristian", "url": "https://seclists.org/oss-sec/2026/q2/8", "date": "2026-04-02", "published_at": "2026-04-02T11:24:50Z", "sentiment": { "label": "positive", "score": 0.723, "confidence": 0.72 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Sachet Water Prices to Rise From Monday as Polymer Crisis Bites", "description": "Ghanaians who rely on sachet water — the majority of the country’s drinking water consumers — will dig deeper into their pockets from Monday, April 6, 2026, after the National Association of Sachet and Packaged Water Producers (NASPAWAP) announced an upward r…", "url": "https://thechronicle.com.gh/sachet-water-prices-to-rise-from-monday-as-polymer-crisis-bites/", "date": "2026-04-02", "published_at": "2026-04-02T09:25:20Z", "sentiment": { "label": "negative", "score": -0.625, "confidence": 0.62 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.2.1", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.2.1/", "date": "2026-04-02", "published_at": "2026-04-02T08:02:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "PAC Invites Two Public Officials Over GH¢8.2m Toilet Contracts", "description": "A GH¢8.2 million ‘Toilet-for-All’ contract scandal has erupted at the Public Accounts Committee (PAC), after government officials admitted they could not produce key documents backing the transactions, claiming the records had been transferred to archives. Th…", "url": "https://thechronicle.com.gh/pac-invites-two-public-officials-over-gh¢8-2m-toilet-contracts/", "date": "2026-04-02", "published_at": "2026-04-02T06:33:45Z", "sentiment": { "label": "negative", "score": -0.34, "confidence": 0.34 } }, { "source": "news", "source_name": "Pypi.org", "title": "acp-gh 1.6.0", "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command", "url": "https://pypi.org/project/acp-gh/1.6.0/", "date": "2026-04-02", "published_at": "2026-04-02T04:30:35Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: MinimumReleaseAge-style protection for Agent Skills", "description": "Article URL: https://github.com/skill-mill/agent-skill-porter\nComments URL: https://news.ycombinator.com/item?id=47604187\nPoints: 1\n# Comments: 1", "url": "https://github.com/skill-mill/agent-skill-porter", "date": "2026-04-01", "published_at": "2026-04-01T17:52:26Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.2.0", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.2.0/", "date": "2026-04-01", "published_at": "2026-04-01T13:32:49Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered 0.3.0", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/0.3.0/", "date": "2026-04-01", "published_at": "2026-04-01T10:11:23Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Aura Reports Updated Mineral Reserves and Mineral Resources For The Year-Ended 2025, Highlighting year of Significant Growth in Mineral Reserve and Resource Portfolio", "description": "Aura Reports Updated Mineral Reserves and Mineral Resources For The Year-Ended 2025, Highlighting year of Significant Growth in Mineral Reserve and Resourc", "url": "https://www.globenewswire.com/news-release/2026/04/01/3266406/0/en/Aura-Reports-Updated-Mineral-Reserves-and-Mineral-Resources-For-The-Year-Ended-2025-Highlighting-year-of-Significant-Growth-in-Mineral-Reserve-and-Resource-Portfolio.html", "date": "2026-04-01", "published_at": "2026-04-01T10:05:00Z", "sentiment": { "label": "positive", "score": 0.778, "confidence": 0.78 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered 0.2.0", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/0.2.0/", "date": "2026-04-01", "published_at": "2026-04-01T10:00:45Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered 0.1.0", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/0.1.0/", "date": "2026-04-01", "published_at": "2026-04-01T09:54:56Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-unanswered added to PyPI", "description": "Find GitHub issues where you were @mentioned but haven't replied since", "url": "https://pypi.org/project/gh-unanswered/", "date": "2026-04-01", "published_at": "2026-04-01T09:54:56Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Crossmind-CLI – CLI for X, Reddit, HN API with compact JSON output", "description": "A CLI for fetching data from social platforms (X, Reddit, HN, GitHub, LinkedIn, Product Hunt, etc.) with compressed JSON output. Built because raw GraphQL responses from X are ~3,900 tokens for 10 tweets — this gets it down to ~666 tokens.Features:\n- 15+ plat…", "url": "https://github.com/cross-mind/crossmind-cli", "date": "2026-04-01", "published_at": "2026-04-01T09:43:51Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Politics Halts Rice, Maize Distribution –Agric Ministry Tells PAC", "description": "Proceedings of the Public Accounts Committee (PAC) of Parliament have revealed that political interference disrupted the execution of a major government grain distribution programme, preventing a contracted logistics firm from carrying out its mandate. Offici…", "url": "https://thechronicle.com.gh/politics-halts-rice-maize-distribution-agric-ministry-tells-pac/", "date": "2026-04-01", "published_at": "2026-04-01T02:07:17Z", "sentiment": { "label": "neutral", "score": -0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Nsein chief gives Lower Axim counter three-month ultimatum to vacate his land", "description": "A festering chieftaincy dispute between two paramount stools in Western Region has escalated sharply, raising fears of violence if urgent intervention is not secured. At the centre of the impasse are the Paramount Chief of Nsein, Awulae Agyefi Kwame, and the …", "url": "https://thechronicle.com.gh/nsein-chief-gives-lower-axim-counter-three-month-ultimatum-to-vacate-his-land/", "date": "2026-04-01", "published_at": "2026-04-01T01:00:53Z", "sentiment": { "label": "negative", "score": -0.905, "confidence": 0.91 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Initialize an AI Harness with Forge CLI", "description": "AI agent pipeline scaffolding CLI — detects stack, renders CLAUDE.md, agents, hooks, pipeline scripts, and compliance addons - samahlstrom/forge-cli", "url": "https://github.com/samahlstrom/forge-cli", "date": "2026-03-31", "published_at": "2026-03-31T23:24:44Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: King Louie a local multi-machine AI assistant", "description": "Article URL: https://github.com/the-banana-tool/king-louie\nComments URL: https://news.ycombinator.com/item?id=47593640\nPoints: 1\n# Comments: 0", "url": "https://github.com/the-banana-tool/king-louie", "date": "2026-03-31", "published_at": "2026-03-31T21:23:33Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Anime News Network", "title": "Hosana Tanaka's Megami no Ko Manga Ends With 3rd Volume", "description": "Manga ended serialization in November, final volume shipped on Monday", "url": "https://www.animenewsnetwork.com/news/2026-03-31/hosana-tanaka-megami-no-ko-manga-ends-with-3rd-volume/.235991", "date": "2026-03-31", "published_at": "2026-03-31T21:00:00Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "deepdoc 0.1.1", "description": "Auto-generate beautiful docs from any codebase", "url": "https://pypi.org/project/deepdoc/", "date": "2026-03-31", "published_at": "2026-03-31T19:59:23Z", "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.1.3", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.1.3/", "date": "2026-03-31", "published_at": "2026-03-31T19:51:32Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit 0.1.2", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/0.1.2/", "date": "2026-03-31", "published_at": "2026-03-31T19:09:09Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-audit added to PyPI", "description": "GitHub audit, governance, and inventory for organizations", "url": "https://pypi.org/project/gh-audit/", "date": "2026-03-31", "published_at": "2026-03-31T19:09:05Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Guardant Health (GH) and Verana Health Announces New Partnership", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_eddc6600-b47b-4adb-920c-3402b82dbd0c", "date": "2026-03-31", "published_at": "2026-03-31T15:06:18Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Precision Medicine Software Market Outlook 2026-2030 & 2035 - Philips, Palantir Technologies, and Tempus Labs Lead the $2.82 Billion Industry", "description": "Growth is fueled by advancements in genomic technologies, rising precision oncology, and focus on interoperable healthcare systems Growth is fueled by advancements in genomic technologies, rising precision oncology, and focus on interoperable healthcare syste…", "url": "https://www.globenewswire.com/news-release/2026/03/31/3265764/28124/en/Precision-Medicine-Software-Market-Outlook-2026-2030-2035-Philips-Palantir-Technologies-and-Tempus-Labs-Lead-the-2-82-Billion-Industry.html", "date": "2026-03-31", "published_at": "2026-03-31T15:04:00Z", "sentiment": { "label": "positive", "score": 0.637, "confidence": 0.64 } }, { "source": "news", "source_name": "Plos.org", "title": "The adapt-to-nutrient NRPS-like secondary metabolite gene cluster facilitates Verticillium dahliae adaptation to different nutrient environments", "description": "Author summary Verticillium dahliae is an economically significant phytopathogen that is widely distributed. The fungus adjusts and adapts its survival strategy according to the surrounding environment. Transcriptome data revealed that the core biosynthetic g…", "url": "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1011930", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "Plos.org", "title": "Biobanking of gynecologic cancer biospecimens: Development, quality control, and translational applications", "description": "Introduction This study presents a nationwide infrastructure for the collection and utilization of gynecologic cancer biospecimens, established through the Korea Biobank Project. We comprehensively describe the biobanking strategy, quality control protocols, …", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345861", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "Plos.org", "title": "Determination of factors that allow cryogenic nanoscopy with high power illumination without devitrification", "description": "Cryogenic fluorescence nanoscopy, also known as super-resolution fluorescence light microscopy, has been demonstrated to be useful to close the resolution gap in cryogenic correlative light and electron microscopy (CLEM). Importantly, under cryogenic conditio…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0344631", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "positive", "score": 0.832, "confidence": 0.83 } }, { "source": "news", "source_name": "Plos.org", "title": "New Histone H4 variant and H2B variant Exhibits distinct genomic distributions, chromatin affinities, and dynamics throughout life and cell cycle of Trypanosoma cruzi", "description": "Author summary Chromatin is composed of a group of proteins called histones that are involved in compacting DNA and thereby affecting many DNA-associated mechanisms, such as replication and transcription. Histone variants share distinct primary sequences from…", "url": "https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1013310", "date": "2026-03-31", "published_at": "2026-03-31T14:00:00Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: \"Have your LLM talk to my LLM\"", "description": "Article URL: https://github.com/dvelton/rendezvous\nComments URL: https://news.ycombinator.com/item?id=47587094\nPoints: 1\n# Comments: 1", "url": "https://github.com/dvelton/rendezvous", "date": "2026-03-31", "published_at": "2026-03-31T13:30:31Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "json-object-mapper added to PyPI", "description": "Attribute-style access wrapper for JSON-like data with dot-path set/delete and safe defaults", "url": "https://pypi.org/project/json-object-mapper/", "date": "2026-03-31", "published_at": "2026-03-31T10:09:56Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: HolyCode – OpenCode in Docker. Use your Claude subscription. 30 tools", "description": "HolyCode is a Docker image that wraps OpenCode (https://opencode.ai), an AI coding agent with a web UI. It ships with 30+ dev tools pre-installed, a headless Chromium/Xvfb/Playwright stack, s6-overlay for process supervision, and UID/GID remapping for correct…", "url": "https://github.com/CoderLuii/HolyCode", "date": "2026-03-31", "published_at": "2026-03-31T08:29:46Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Heath Goldfields Has Brought Renewed Hope To Prestea-Bogoso -Group", "description": "Hope has been rekindled in the Prestea-Bogoso enclave following the rapid revival of mining operations by Heath Goldfields, with residents and stakeholders calling on government to safeguard the company’s growing investment. At a press conference held yesterd…", "url": "https://thechronicle.com.gh/heath-goldfields-has-brought-renewed-hope-to-prestea-bogoso-group/", "date": "2026-03-31", "published_at": "2026-03-31T08:04:42Z", "sentiment": { "label": "positive", "score": 0.844, "confidence": 0.84 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Tarkwa Court Remands Two Students Over Supermarket Break-In and Theft", "description": "The Circuit Court in Tarkwa has remanded two young men, including a student of Takoradi Technical University, into custody for allegedly stealing cash and goods from a local supermarket. The accused, Kingsford Quarshie, also known as “Cash Money,” 21, a miner…", "url": "https://thechronicle.com.gh/tarkwa-court-remands-two-students-over-supermarket-break-in-and-theft/", "date": "2026-03-31", "published_at": "2026-03-31T07:56:13Z", "sentiment": { "label": "negative", "score": -0.71, "confidence": 0.71 } }, { "source": "news", "source_name": "Droppedasbaby.com", "title": "Accidentally created my first fork bomb with Claude Code", "description": "Accidentally created my first fork bomb with Claude Code, bricked my computer overnight, and somehow built useful tools along the way.", "url": "https://www.droppedasbaby.com/posts/2602-01/", "date": "2026-03-31", "published_at": "2026-03-31T07:40:18Z", "sentiment": { "label": "negative", "score": -0.649, "confidence": 0.65 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Claudebase: Sync your Claude Code env across machines via GitHub", "description": "Article URL: https://github.com/rohithzr/claudebase\nComments URL: https://news.ycombinator.com/item?id=47583664\nPoints: 1\n# Comments: 0", "url": "https://github.com/rohithzr/claudebase", "date": "2026-03-31", "published_at": "2026-03-31T06:53:23Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "deathstar-ai added to PyPI", "description": "Secure AWS-hosted remote AI coding workstation with a provider-agnostic local CLI.", "url": "https://pypi.org/project/deathstar-ai/", "date": "2026-03-31", "published_at": "2026-03-31T06:15:04Z", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "news", "source_name": "ComingSoon.net", "title": "Sofia Mattsson’s New Soap Casting Revealed After General Hospital Exit", "description": "Sofia Mattsson is making a dramatic move after her seven-year stint as Sasha Gilmore on General Hospital. After exiting the ABC drama, Mattsson has been busy preparing for her next chapter. With her extensive experience in daytime drama, the Swedish-born actr…", "url": "https://www.comingsoon.net/tv/news/2114104-sofia-mattsson-cast-days-of-our-lives-general-hospital", "date": "2026-03-31", "published_at": "2026-03-31T05:56:58Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Agent-Reach - Give your AI agent eyes to see the entire internet", "description": "Give your AI agent eyes to see the entire internet. Read & search Twitter, Reddit, YouTube, GitHub, Bilibili, XiaoHongShu — one CLI, zero API fees. - Panniantong/Agent-Reach", "url": "https://github.com/Panniantong/Agent-Reach", "date": "2026-03-31", "published_at": "2026-03-31T05:47:01Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Deadline", "title": "Sofia Mattsson Joins ‘Days Of Our Lives’ Following ‘General Hospital’ Departure", "description": "Salem is getting a new resident in Sofia Mattsson. The former General Hospital actress will be jumping networks to NBC’s Days of our Lives, the soap announced in a joint post shared to Instagram. “Sofia Mattsson is making her way to Salem early next year! ⏳…", "url": "http://deadline.com/2026/03/sofia-mattsson-days-of-our-lives-cast-addition-1236769635/", "date": "2026-03-31", "published_at": "2026-03-31T02:48:43Z", "sentiment": { "label": "positive", "score": 0.4, "confidence": 0.4 } }, { "source": "news", "source_name": "Pypi.org", "title": "aimio-py added to PyPI", "description": "Python bindings for the Numerics88 AimIO C++ library", "url": "https://pypi.org/project/aimio-py/", "date": "2026-03-31", "published_at": "2026-03-31T02:47:14Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "ez-stack 0.2.11", "description": "Stacked PRs for GitHub — agent-first CLI for parallel development", "url": "https://pypi.org/project/ez-stack/", "date": "2026-03-31", "published_at": "2026-03-31T00:17:47Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "acp-gh 1.5.0", "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command", "url": "https://pypi.org/project/acp-gh/1.5.0/", "date": "2026-03-30", "published_at": "2026-03-30T23:12:09Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Police Gun Down Suspected Armed Robber on Atebubu–Ejura Highway", "description": "The Ghana Police Service has allegedly shot dead a suspected notorious armed robber, Osman Amadu, popularly known as “Manu,” during an intelligence-led operation along the Atebubu–Ejura highway. According to police reports, the incident occurred on March 18, …", "url": "https://thechronicle.com.gh/police-gun-down-suspected-armed-robber-on-atebubu-ejura-highway/", "date": "2026-03-30", "published_at": "2026-03-30T17:22:17Z", "sentiment": { "label": "negative", "score": -0.95, "confidence": 0.95 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-bin 2.89.0", "description": "A thin wrapper to distribute https://github.com/cli/cli via pip.", "url": "https://pypi.org/project/gh-bin/2.89.0/", "date": "2026-03-30", "published_at": "2026-03-30T16:16:36Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "wizardenv added to PyPI", "description": "A powerful AI SDK with vision, speech, and multi-backend support", "url": "https://pypi.org/project/wizardenv/", "date": "2026-03-30", "published_at": "2026-03-30T15:03:36Z", "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "news", "source_name": "Stephenjude.me", "title": "How to Setup PIE for PHP Extensions on macOS", "description": "Pie is the official PHP extension installer and the replacement for PECL. In this article, I will show you how to get Pie up and running on your local machine.", "url": "https://stephenjude.me/articles/how-to-setup-pie-for-php-extensions-on-macos?utm_source=laravelnews&utm_medium=link&utm_campaign=laravelnews", "date": "2026-03-30", "published_at": "2026-03-30T13:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Donors cheer up SHS Arts students for decorating Asokwa Interchange", "description": "Individuals and institutions have trooped to the Asokwa Interchange with food, drinks and cash donations to support Visual Arts students from Senior High Schools who are engaged in decorating the Asokwa Interchange. The project forms part of the novelle Ashan…", "url": "https://thechronicle.com.gh/donors-cheer-up-shs-arts-students-for-decorating-asokwa-interchange/", "date": "2026-03-30", "published_at": "2026-03-30T12:05:55Z", "sentiment": { "label": "positive", "score": 0.827, "confidence": 0.83 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Filmmakers Summit Held in Kumasi to boost Kumawood Industry", "description": "A Filmmakers Summit has been held in Kumasi to revitalise the Ghanaian film industry as part of the Ashanti Festival 2026. Secretary to the Kumawood Board of Directors, Emmanuel Opoku Anane, said the summit is designed to enhance the industry’s vibrancy and s…", "url": "https://thechronicle.com.gh/filmmakers-summit-held-in-kumasi-to-boost-kumawood-industry/", "date": "2026-03-30", "published_at": "2026-03-30T12:01:36Z", "sentiment": { "label": "positive", "score": 0.71, "confidence": 0.71 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Gene Panel Market Size to Projected Reach USD 17.18 Billion by 2035, Driven by Precision Medicine Adoption – SNS Insider", "description": "Rising demand for early disease detection, expanding oncology applications, and rapid advancements in next-generation sequencing technologies propel market growth at 16.69% CAGR. Rising demand for early disease detection, expanding oncology applications, and …", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264508/0/en/Gene-Panel-Market-Size-to-Projected-Reach-USD-17-18-Billion-by-2035-Driven-by-Precision-Medicine-Adoption-SNS-Insider.html", "date": "2026-03-30", "published_at": "2026-03-30T11:12:00Z", "sentiment": { "label": "positive", "score": 0.178, "confidence": 0.18 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Ag.sh – All-in-one CLI tool to do parallelised AI development with ease", "description": "Command-line ADE tooling to run multiple Claude Code/AI agents in parallel - each in its own isolated git worktree. Spawn, manage, and orchestrate AI-powered development across concurrent tasks wi...", "url": "https://github.com/andrewhathaway/ag.sh", "date": "2026-03-30", "published_at": "2026-03-30T11:01:13Z", "sentiment": { "label": "positive", "score": 0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook", "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…", "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html", "date": "2026-03-30", "published_at": "2026-03-30T08:58:00Z", "sentiment": { "label": "positive", "score": 0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "Pythonbytes.fm", "title": "Python Bytes: #475 Haunted warehouses", "description": "News and announcements from the Python community for the week of Mar 30th, 2026", "url": "https://pythonbytes.fm/episodes/show/475/haunted-warehouses", "date": "2026-03-30", "published_at": "2026-03-30T08:00:00Z", "sentiment": { "label": "negative", "score": -0.477, "confidence": 0.48 } }, { "source": "news", "source_name": "Github.com", "title": "simonw/claude-code-transcripts: Tools for publishing transcripts for Claude Code sessions", "description": "Tools for publishing transcripts for Claude Code sessions - simonw/claude-code-transcripts", "url": "https://github.com/simonw/claude-code-transcripts", "date": "2026-03-30", "published_at": "2026-03-30T05:47:01Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-worktree 0.3.1", "description": "github CLI extension for worktrees", "url": "https://pypi.org/project/gh-worktree/0.3.1/", "date": "2026-03-29", "published_at": "2026-03-29T22:48:33Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "claude-podman added to PyPI", "description": "Run Claude Code CLI in a Podman container with tmux, GitHub access, and persistent config", "url": "https://pypi.org/project/claude-podman/", "date": "2026-03-29", "published_at": "2026-03-29T19:35:55Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Baton – A daemon that sends Claude to fix your GitHub issues", "description": "I got tired of the context-switching loop: pick an issue, read the context, write the code, open a PR, pick the next one. So I built Baton — a Python daemon that polls your GitHub issue tracker and dispatches Claude Code agents to work on them autonomously.Ho…", "url": "https://github.com/mraza007/baton", "date": "2026-03-29", "published_at": "2026-03-29T16:57:05Z", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "ansel-cli added to PyPI", "description": "don't leave crumbs in the woods", "url": "https://pypi.org/project/ansel-cli/", "date": "2026-03-29", "published_at": "2026-03-29T16:47:06Z", "sentiment": { "label": "neutral", "score": 0.038, "confidence": 0.04 } }, { "source": "news", "source_name": "Github.com", "title": "GitHub - axeldelafosse/loop: Dead-simple Bun CLI that runs Codex and Claude Code in a loop. · GitHub", "description": "axeldelafosse/loop: Dead-simple Bun CLI that runs Codex and Claude Code in a loop. https://ift.tt/KJUYeRg ai, codex, claude.code, programming", "url": "https://github.com/axeldelafosse/loop", "date": "2026-03-29", "published_at": "2026-03-29T05:47:02Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-worktree 0.3.0", "description": "github CLI extension for worktrees", "url": "https://pypi.org/project/gh-worktree/0.3.0/", "date": "2026-03-28", "published_at": "2026-03-28T23:26:34Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "fastmvc-cli added to PyPI", "description": "FastMVC CLI — interactive FastAPI project generator and tooling", "url": "https://pypi.org/project/fastmvc-cli/", "date": "2026-03-28", "published_at": "2026-03-28T16:33:56Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Github.com", "title": "Show HN: Open Source 'Conductor + Ghostty'", "description": "Our team works with Claude Code, Codex, Gemini all day.\nWe love Ghostty, but wanted something where we could work in multiple worktree at once and have multiple agents run.We decided to open source the internal team we use. Hope you might find it useful. Free…", "url": "https://github.com/stablyai/orca", "date": "2026-03-27", "published_at": "2026-03-27T22:26:40Z", "sentiment": { "label": "positive", "score": 0.883, "confidence": 0.88 } }, { "source": "news", "source_name": "Pypi.org", "title": "acp-gh 1.4.0", "description": "Automatic Commit Pusher (acp) - CLI tool to create GitHub PRs from staged changes in a single command", "url": "https://pypi.org/project/acp-gh/1.4.0/", "date": "2026-03-27", "published_at": "2026-03-27T21:39:52Z", "sentiment": { "label": "positive", "score": 0.511, "confidence": 0.51 } }, { "source": "news", "source_name": "Github.com", "title": "Velxio 2.0 – Emulate Arduino, ESP32, and Raspberry Pi 3 in the Browser", "description": "Emulate Arduino, ESP32 & Raspberry Pi. in your browser. Write code, compile, and run on 19 real boards — Arduino Uno, ESP32, ESP32-C3, Raspberry Pi Pico, Raspberry Pi 3, and more. No hardware, ...", "url": "https://github.com/davidmonterocrespo24/velxio", "date": "2026-03-27", "published_at": "2026-03-27T20:44:33Z", "sentiment": { "label": "negative", "score": -0.36, "confidence": 0.36 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research", "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html", "date": "2026-03-27", "published_at": "2026-03-27T16:31:00Z", "sentiment": { "label": "negative", "score": -0.945, "confidence": 0.95 } }, { "source": "news", "source_name": "Plos.org", "title": "Glucocorticoid-Induced alterations in DNA methylation in the H19 promoter of Bone Marrow-Derived Mesenchymal Stem Cells are associated with the pathogenesis of osteonecrosis", "description": "Background Glucocorticoid (GC)-induced osteonecrosis of the femoral head (ONFH) involves bone marrow-derived mesenchymal stem cell (BMSC) apoptosis and dysregulated osteo-adipogenic differentiation. While aberrant H19 promoter methylation and expression have …", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345372", "date": "2026-03-27", "published_at": "2026-03-27T14:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Zinc Chemicals Market to Reach USD 16.17 Billion by 2035, Fueled by Rising Demand in Rubber, Agriculture, and Industrial Applications | Research by SNS Insider", "description": "The Zinc Chemicals Market is growing steadily as demand rises for zinc-based fertilizers, rubber additives, and industrial formulations, with the U.S. segment increasing from USD 1.86 billion in 2025 to USD 2.82 billion by 2035. The Zinc Chemicals Market is g…", "url": "https://www.globenewswire.com/news-release/2026/03/27/3263802/0/en/Zinc-Chemicals-Market-to-Reach-USD-16-17-Billion-by-2035-Fueled-by-Rising-Demand-in-Rubber-Agriculture-and-Industrial-Applications-Research-by-SNS-Insider.html", "date": "2026-03-27", "published_at": "2026-03-27T13:30:00Z", "sentiment": { "label": "negative", "score": -0.052, "confidence": 0.05 } }, { "source": "news", "source_name": "Pypi.org", "title": "caalm added to PyPI", "description": "Carbohydrate Activity Annotation with protein Language Models", "url": "https://pypi.org/project/caalm/", "date": "2026-03-27", "published_at": "2026-03-27T08:29:51Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Two Jailed for Stealing Motorbike Worth GH¢10,500", "description": "The Circuit Court at Dansoman has sentenced two young men to prison for stealing a motorbike valued at GH¢10,500. The convicts, Abdul Aziz Osman, 20, unemployed and Abdul Aziz Mohammed, 22, also unemployed, were sentenced by the court presided over by Her Hon…", "url": "https://thechronicle.com.gh/two-jailed-for-stealing-motorbike-worth-gh¢10500/", "date": "2026-03-27", "published_at": "2026-03-27T08:00:45Z", "sentiment": { "label": "negative", "score": -0.883, "confidence": 0.88 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Fashion Designer remanded over alleged possession, use of counterfeit money", "description": "The Circuit Court in Tarkwa, presided over by Her Honour Bernice Mensimah Ackon, has remanded a 40-year-old fashion designer, Grace Arthur, into custody for allegedly possessing and uttering counterfeit Ghana cedi notes at Wasa Akropong in the Western Region.…", "url": "https://thechronicle.com.gh/fashion-designer-remanded-over-alleged-possession-use-of-counterfeit-money/", "date": "2026-03-27", "published_at": "2026-03-27T07:58:51Z", "sentiment": { "label": "positive", "score": 0.758, "confidence": 0.76 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Businessman Jailed 24 Months for GH¢180,000 Visa Fraud", "description": "The Dansoman Circuit Court has sentenced a 29-year-old businessman, Charles Komla Asigbey, to 24 months imprisonment for defrauding seven persons of GH¢180,000 under the pretext of securing visas for them to travel abroad. The court, presided over by Her Hono…", "url": "https://thechronicle.com.gh/businessman-jailed-24-months-for-gh¢180000-visa-fraud/", "date": "2026-03-27", "published_at": "2026-03-27T07:56:52Z", "sentiment": { "label": "negative", "score": -0.9, "confidence": 0.9 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "ECG delivers an impressive operational performance in 2025", "description": "The Eastern Regional office of the Electricity Company of Ghana (ECG) has delivered an impressive operational performance in 2025, underpinned by improved power stability, strategic infrastructure investments, and a renewed crackdown on illegal electricity us…", "url": "https://thechronicle.com.gh/ecg-delivers-an-impressive-operational-performance-in-2025/", "date": "2026-03-27", "published_at": "2026-03-27T07:46:12Z", "sentiment": { "label": "positive", "score": 0.727, "confidence": 0.73 } }, { "source": "news", "source_name": "ComingSoon.net", "title": "GH’s Marco Star Adrian Anchondo Gets Tribute From Boyfriend After Exit", "description": "Fans have bid farewell to General Hospital‘s Marco, portrayed by Adrian Anchondo, and his boyfriend has now shared his reaction to his exit. Fellow soap opera star Colton Little shared an emotional tribute after Anchondo’s surprise departure from GH. Adrian A…", "url": "https://www.comingsoon.net/tv/news/2112893-general-hospital-gh-adrian-anchondo-leave-exit-marco-death-reaction", "date": "2026-03-27", "published_at": "2026-03-27T05:24:50Z", "sentiment": { "label": "positive", "score": 0.713, "confidence": 0.71 } }, { "source": "news", "source_name": "Thechronicle.com.gh", "title": "Haruna Iddrisu throws $27,000 lifeline for fourth surgery of six-year-old boy", "description": "The Member of Parliament for Tamale North, Haruna Iddrisu, has funded a fourth life-saving surgery for a six-year-old boy, Abdula Hannan at the KomfoAnokye Teaching Hospital.The little boy has a prolonged medical condition caused by accidental ingestion of a …", "url": "https://thechronicle.com.gh/haruna-iddrisu-throws-27000-lifeline-for-fourth-surgery-of-six-year-old-boy/", "date": "2026-03-27", "published_at": "2026-03-27T00:41:00Z", "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "news", "source_name": "Nature.com", "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial", "description": "In the nonpivotal stage 1 of the randomized phase 3 PRESERVE-003 trial, patients with immunochemotherapy-resistant metastatic squamous non-small cell lung cancer without actionable genomic alterations treated with the next-generation, pH-sensitive anti-CTLA-4…", "url": "https://www.nature.com/articles/s41591-026-04323-8", "date": "2026-03-27", "published_at": "2026-03-27T00:00:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "Royal Society of Chemistry", "title": "Atmosphere-dependent synthesis and crystallization behavior of silica nanoparticles derived from rice husk biomass", "description": "RSC Adv., 2026, 16,16874-16886DOI: 10.1039/D6RA00367B, Paper Open Access   This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.Fuad Hama Shareef Radha, Mohammad Tahir Kareem, Omed Gh. AbdullahThis work on sustainable nanomat…", "url": "https://pubs.rsc.org/en/content/articlelanding/2026/ra/d6ra00367b", "date": "2026-03-27", "published_at": "2026-03-27T00:00:00Z", "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "news", "source_name": "Pypi.org", "title": "ticktick-agent-cli added to PyPI", "description": "Agent-native CLI for TickTick task management — full API coverage via V1 + V2", "url": "https://pypi.org/project/ticktick-agent-cli/", "date": "2026-03-26", "published_at": "2026-03-26T23:19:31Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results", "description": "NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:", "url": "https://www.globenewswire.com/news-release/2026/03/26/3263407/0/en/IMDX-Submits-GraftAssureDx-for-FDA-Review-and-Reports-Q4-2025-Results.html", "date": "2026-03-26", "published_at": "2026-03-26T20:05:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Pypi.org", "title": "gh-license 0.4.0", "description": "Scan github, bitbucket or other providers repositories for missing license files and add them", "url": "https://pypi.org/project/gh-license/0.4.0/", "date": "2026-03-26", "published_at": "2026-03-26T18:26:05Z", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "news", "source_name": "Pypi.org", "title": "rcpilot added to PyPI", "description": "Lightweight self-hosted session manager for Claude Code Remote Control", "url": "https://pypi.org/project/rcpilot/", "date": "2026-03-26", "published_at": "2026-03-26T17:43:19Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Ssrf.dev", "title": "個人的にGitHub Actionsまわりで気をつけていること | ssrf.dev", "description": "目次ghalint / actionlintに頼る3rd party actionをできるだけ使わないSecretsにKeyを置かないやろうと思っているけど徹底できていないことRequire actions to be pinned to a full-length commit SHAの有効化branch ruleset / push rulesetghalint / actionlintを全リポジトリで回すさいごに 2026年も引き続きGitHub Ac...", "url": "https://ssrf.dev/posts/2026/03/27/personal-gha-security-tips/", "date": "2026-03-26", "published_at": "2026-03-26T16:50:38Z", "sentiment": { "label": "positive", "score": 0.599, "confidence": 0.6 } }, { "source": "news", "source_name": "Plos.org", "title": "Holding it all together: Family caregivers’ support needs after very early supported discharge post stroke", "description": "Background Early supported discharge (ESD) facilitates the transition from specialized stroke units to home-based rehabilitation in familiar environments. While ESD has shown positive outcomes for people with stroke, little is known about how their family car…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345795", "date": "2026-03-26", "published_at": "2026-03-26T14:00:00Z", "sentiment": { "label": "positive", "score": 0.88, "confidence": 0.88 } }, { "source": "news", "source_name": "Plos.org", "title": "Repurposing mebendazole to reprogram oncogenic and tumor-suppressor networks: Multi-cancer insights from ENOX2, MMP2, RASSF1A, WFDC10A and METTL7A", "description": "Background Cancer progression involves coordinated regulation of oncogenes and tumor suppressors. This study explores the interplay of ENOX2 (ecto-NADH oxidase disulfide-thiol exchanger 2), MMP2 (matrix metalloproteinase-2), and regulatory genes Ras Associati…", "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0345701", "date": "2026-03-26", "published_at": "2026-03-26T14:00:00Z", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "news", "source_name": "Plos.org", "title": "Cell cycle dynamics regulate H3K27 and H3K9 histone modifications in Drosophila", "description": "Previous studies have established a link between cell cycle progression and histone modification dynamics, but how this is regulated in vivo has remained largely explored. This study shows that the levels of H3K27ac, H3K27me3, and H3K9me3 are tightly linked t…", "url": "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003371", "date": "2026-03-26", "published_at": "2026-03-26T14:00:00Z", "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "pubmed", "pmid": "41935073", "title": "IL1R1 blockade augments CD40 agonist mediated immunity in pancreatic cancer.", "authors": "Boda AR et al.", "journal": "Scientific reports", "date": "2026 Apr 4", "url": "https://pubmed.ncbi.nlm.nih.gov/41935073/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41934464", "title": "Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee.", "authors": "McMahon RA et al.", "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41934464/", "sentiment": { "label": "negative", "score": -0.718, "confidence": 0.72 } }, { "source": "pubmed", "pmid": "41933595", "title": "Safety profile of KRAS G12C inhibitors combined with thoracic radiation therapy.", "authors": "Miller DG et al.", "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933595/", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "pubmed", "pmid": "41933194", "title": "Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.", "authors": "Johnson ML et al.", "journal": "British journal of cancer", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41933194/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41931739", "title": "Longitudinal, Retrospective Use of a Circulating Tumor DNA Methylation Signature Successfully Captures Small Cell Evolution in a Patient With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer.", "authors": "Patil T et al.", "journal": "JCO precision oncology", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41931739/", "sentiment": { "label": "negative", "score": -0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41931218", "title": "Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale.", "authors": "Del Re M et al.", "journal": "Drugs", "date": "2026 Apr 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41931218/", "sentiment": { "label": "negative", "score": -0.402, "confidence": 0.4 } }, { "source": "pubmed", "pmid": "41925922", "title": "Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.", "authors": "Hörner M et al.", "journal": "Breast cancer research and treatment", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41925922/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41924551", "title": "Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.", "authors": "Eslinger C et al.", "journal": "Drug design, development and therapy", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41924551/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922144", "title": "Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.", "authors": "Matsubara T et al.", "journal": "ESMO open", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41922144/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41922143", "title": "Comparative efficacy of zanubrutinib plus obinutuzumab versus last prior treatment in relapsed/refractory follicular lymphoma: growth modulation index analysis from the ROSEWOOD study.", "authors": "Trotman J et al.", "journal": "ESMO open", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41922143/", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41917211", "title": "Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.", "authors": "Lopez JS et al.", "journal": "British journal of cancer", "date": "2026 Mar 3", "url": "https://pubmed.ncbi.nlm.nih.gov/41917211/", "sentiment": { "label": "negative", "score": -0.077, "confidence": 0.08 } }, { "source": "pubmed", "pmid": "41917040", "title": "Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER(+) HER2(-) locally-advanced or metastatic breast cancer.", "authors": "Liang J et al.", "journal": "Nature communications", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41917040/", "sentiment": { "label": "negative", "score": -1.0, "confidence": 1.0 } }, { "source": "pubmed", "pmid": "41910021", "title": "A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.", "authors": "Johnson ML et al.", "journal": "Future oncology (London, England)", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41910021/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41903996", "title": "Utility of Circulating Tumor DNA-Based Liquid Biopsies in Patients with Cancer Receiving Immunotherapy.", "authors": "Teixeira MF et al.", "journal": "Surgical oncology clinics of North America", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41903996/", "sentiment": { "label": "negative", "score": -0.791, "confidence": 0.79 } }, { "source": "pubmed", "pmid": "41903301", "title": "Phase Ia/Ib trial of the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M).", "authors": "Kanemura H et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41903301/", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41899521", "title": "Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy.", "authors": "Gandara DR et al.", "journal": "Cancers", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41899521/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41898529", "title": "Genome-Wide CRISPR Screens Identify ABCG2-Mediated Drug Resistance to the Threonine Tyrosine Kinase (TTK) Inhibitor CFI-402257 in Breast Cancer.", "authors": "Thu KL et al.", "journal": "International journal of molecular sciences", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41898529/", "sentiment": { "label": "negative", "score": -0.691, "confidence": 0.69 } }, { "source": "pubmed", "pmid": "41896648", "title": "Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial.", "authors": "Cho BC et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41896648/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41895789", "title": "Comparison of tissue acquisition techniques for Next-Generation Sequencing of non-small cell lung cancer (NSCLC).", "authors": "Bhamani A et al.", "journal": "BMJ open respiratory research", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895789/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41895314", "title": "Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration.", "authors": "Dingemans AC et al.", "journal": "The Lancet. Respiratory medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41895314/", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "pubmed", "pmid": "41892875", "title": "Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609).", "authors": "Swiecicki PL et al.", "journal": "Cancer", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41892875/", "sentiment": { "label": "negative", "score": -0.67, "confidence": 0.67 } }, { "source": "pubmed", "pmid": "41883872", "title": "Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.", "authors": "Qadri F et al.", "journal": "Therapeutic advances in medical oncology", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41883872/", "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41882405", "title": "Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.", "authors": "Park W et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41882405/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41880871", "title": "Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).", "authors": "Kito Y et al.", "journal": "European journal of cancer (Oxford, England : 1990)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41880871/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41876649", "title": "AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial.", "authors": "Woznitza N et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41876649/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41874648", "title": "Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).", "authors": "Mollica V et al.", "journal": "Cancer immunology, immunotherapy : CII", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41874648/", "sentiment": { "label": "positive", "score": 0.25, "confidence": 0.25 } }, { "source": "pubmed", "pmid": "41872602", "title": "Implementation of the NHS England Lung Cancer Screening Programme over 5 years.", "authors": "Lee RW et al.", "journal": "Nature medicine", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41872602/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41871874", "title": "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.", "authors": "McKay RR et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41871874/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41870735", "title": "Efficacy and safety of trastuzumab biosimilar CT-P6 plus SOX or CapeOX in HER2-positive advanced gastric cancer: a multicenter phase II KSCC-TROX study.", "authors": "Oki E et al.", "journal": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41870735/", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "pubmed", "pmid": "41866411", "title": "Efficacy and safety of peptide radionuclide therapy with (177)Lu-DOTATATE in Japanese patients with advanced neuroendocrine neoplasm: a multicenter retrospective study (JON2203-N).", "authors": "Okamoto K et al.", "journal": "Journal of gastroenterology", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41866411/", "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41864749", "title": "Survival outcome of VATS compared with open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials.", "authors": "Harris RA et al.", "journal": "Lancet (London, England)", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41864749/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41861751", "title": "Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia.", "authors": "Rugo HS et al.", "journal": "ESMO open", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861751/", "sentiment": { "label": "negative", "score": -0.382, "confidence": 0.38 } }, { "source": "pubmed", "pmid": "41861516", "title": "Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.", "authors": "Lee P et al.", "journal": "EBioMedicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41861516/", "sentiment": { "label": "negative", "score": -0.46, "confidence": 0.46 } }, { "source": "pubmed", "pmid": "41858873", "title": "Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.", "authors": "Sanchez-Cespedes M et al.", "journal": "JTO clinical and research reports", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41858873/", "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "pubmed", "pmid": "41851476", "title": "Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study.", "authors": "Shore ND et al.", "journal": "Prostate cancer and prostatic diseases", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41851476/", "sentiment": { "label": "negative", "score": -0.751, "confidence": 0.75 } }, { "source": "pubmed", "pmid": "41849281", "title": "Implementing a successful patient navigation program for follow-up colonoscopy: Lessons from the PRECISE study.", "authors": "Thompson JH et al.", "journal": "PloS one", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41849281/", "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "pubmed", "pmid": "41847154", "title": "Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in EGFR-Mutant Unresectable Stage III NSCLC.", "authors": "Takamori S et al.", "journal": "JTO clinical and research reports", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41847154/", "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "pubmed", "pmid": "41843267", "title": "SEOM-TTCC clinical guidelines for the treatment of head and neck cancer (2025).", "authors": "Arrazubi V et al.", "journal": "Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41843267/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41840238", "title": "First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.", "authors": "Shitara K et al.", "journal": "Nature medicine", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41840238/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41832914", "title": "Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.", "authors": "Boku S et al.", "journal": "Discover oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41832914/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } }, { "source": "pubmed", "pmid": "41830752", "title": "Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer.", "authors": "Brufsky A et al.", "journal": "Breast (Edinburgh, Scotland)", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41830752/", "sentiment": { "label": "negative", "score": -0.691, "confidence": 0.69 } }, { "source": "pubmed", "pmid": "41830429", "title": "Telemedicine as a gateway to early-phase oncology trials: lessons from 14 000 patients and future directions for global access and equity.", "authors": "Torrado C et al.", "journal": "The oncologist", "date": "2026 Mar 9", "url": "https://pubmed.ncbi.nlm.nih.gov/41830429/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41825704", "title": "Coupled-enzyme assay for MTAP activity in biological samples.", "authors": "Gilaj N et al.", "journal": "Analytical biochemistry", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825704/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41825178", "title": "Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort.", "authors": "Araújo BJ et al.", "journal": "Lung cancer (Amsterdam, Netherlands)", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41825178/", "sentiment": { "label": "negative", "score": -0.511, "confidence": 0.51 } }, { "source": "pubmed", "pmid": "41819545", "title": "Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609).", "authors": "Chae YK et al.", "journal": "Journal for immunotherapy of cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41819545/", "sentiment": { "label": "negative", "score": -0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41819104", "title": "Cell-type-specific transposon demethylation and TAD remodeling in aging mouse brain.", "authors": "Zeng Q et al.", "journal": "Cell", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41819104/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41817930", "title": "ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.", "authors": "Kuemmel S et al.", "journal": "Annals of surgical oncology", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41817930/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41810446", "title": "Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars.", "authors": "Moura CS et al.", "journal": "World journal of gastroenterology", "date": "2026 Mar 7", "url": "https://pubmed.ncbi.nlm.nih.gov/41810446/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41809424", "title": "Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era.", "authors": "Okemoto D et al.", "journal": "Gastroenterology report", "date": "2026-04-06", "url": "https://pubmed.ncbi.nlm.nih.gov/41809424/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41808570", "title": "Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.", "authors": "Gandara DR et al.", "journal": "Cancer", "date": "2026 Mar 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41808570/", "sentiment": { "label": "negative", "score": -0.527, "confidence": 0.53 } } ] } }